Veracyte

IPO

Empowering clinicians to diagnose and treat cancer with confidence

Public · South San Francisco, United States · Founded 2008 · $56.3M raised

Employees
501–1000
Founded
2008
Business Model
B2B
Total Funding
$56.3M
Last Round
$28.0M Series CJun 2013
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 5 investors for this company. The full record is or through the API.

About

Veracyte is a global genomic diagnostics company founded in 2008 and headquartered in South San Francisco, California. The company develops and commercializes genomic tests that give clinicians high-confidence insights at critical diagnostic decision points in oncology. Its product portfolio includes the Afirma Genomic Sequencing Classifier for thyroid cancer, Decipher Prostate and Bladder Genomic Classifiers for urologic cancers, the Prosigna Breast Cancer Assay, and the Percepta Nasal Swab Test for lung cancer. Veracyte's tests enable physicians to avoid unnecessary surgeries and guide treatment decisions with greater precision. The company has grown through acquisitions and partnerships to serve patients and clinicians across multiple cancer types globally.

Summary

Veracyte is a Biotech company based in South San Francisco, United States, founded in 2008. It has raised $56.3M in total across 3 rounds, most recently a $28.0M Series C round in Jun 2013. Investors include Kleiner Perkins, Domain Associates and Versant Ventures.

Tech & App Stack

10 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPOOct 2013
$58.7M

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Acquisitions

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$2.1BJun 2026
Caris Life SciencesIPO

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...

Irving, United States1001–5000Diagnostics, Genomics
Growth EquityTotal funding$1.5BApr 2025
Foundation MedicineAcquired

Provides genomic profiling tests and data services to oncologists and biopharma partners to guide...

Cambridge, United States1001–5000Diagnostics, Genomics
Corporate RoundTotal funding$1.1BJan 2015
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Veracyte on Indexed.vc
<a href="https://indexed.vc/companies/veracyte"><img src="https://indexed.vc/api/badge/company/veracyte" alt="Veracyte on Indexed.vc" width="260" height="76" /></a>